ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA),

Status Terminated

Clinical Trial Summary

This is an open label study of ATI-502 Topical Solution for the treatment of AA, AU, and AT with the following goals:

- To assess the safety, tolerability, and efficacy of ATI-502 Topical Solution in subjects with AA, AU or AT following 24 weeks of treatment with ATI-501 Oral Suspension or Placebo Suspension.

- To assess the ability of ATI-502 Topical Solution to maintain or improve hair regrowth in subjects previously treated with ATI-501 Oral Suspension or Placebo Suspension.

Clinical Trial Description

This Phase 2, multicenter, open-label study will evaluate the safety, tolerability, efficacy, and durability of efficacy of ATI-502 Topical Solution, 0.46% for the treatment of alopecia areata (AA), alopecia universalis (AU) and alopecia totalis (AT) in adult subjects who completed 24 weeks of treatment with ATI-501 Oral Suspension or Placebo Suspension.

Subjects who complete 24 weeks of active treatment with ATI-501 Oral Suspension or Placebo Suspension in study ATI-501-AUAT-201 will be assessed for eligibility to enter the study. At Visit 9 in study ATI-501-AUAT-201, subjects who did not experience any adverse events (AEs), serious adverse events (SAEs), or tolerability issues that met study discontinuation criteria in study ATI-501-AUAT-201 and who in the opinion of the investigator are capable of re-growing or maintaining scalp hair and meet the entry criteria are eligible to enroll in this open-label study.

Enrolled subjects will apply ATI-502 Topical Solution, 0.46% BID to the entire scalp and if applicable, the eyebrow(s) and return for safety and efficacy assessments as detailed in the Schedule of Assessments (Table 3). Assessment of response to treatment will be performed at Week 4, Week 8, Week 16, Week 24, and post-treatment Week 28. Safety and tolerability will be evaluated at each study visit by assessment of adverse events, clinical laboratory tests, and vital signs, and at Week 24, and physical examination findings ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03759340
Study type	Interventional
Source	Aclaris Therapeutics, Inc.
Contact
Status	Terminated
Phase	Phase 2
Start date	January 15, 2019
Completion date	September 11, 2019

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05051761` - Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata	Phase 3
Active, not recruiting	`NCT03570749` - A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata	Phase 2/Phase 3
Completed	`NCT02812342` - Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants	Phase 2
Completed	`NCT02350023` - Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata	Phase 4
Completed	`NCT02018042` - An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata	Phase 2
Terminated	`NCT01898806` - Intralesional Steroids in the Treatment of Alopecia Areata	Phase 4
Recruiting	`NCT04011748` - Clinical Application of Stem Cell Educator Therapy in Alopecia Areata	Phase 2
Active, not recruiting	`NCT04517864` - PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA	Phase 2
Not yet recruiting	`NCT05803070` - Topical Cetirizine in Treatment of Localized Alopecia Areata
Not yet recruiting	`NCT05496426` - A Study of KL130008 in Adults With Severe Alopecia Areata	Phase 2
Completed	`NCT04147845` - Transepidermal Delivery of Triamcinolone Acetonide or Platelet Rich Plasma Using Either Fractional Carbon Dioxide Laser or Microneedling in Treatment of Alopecia Areata	N/A
Terminated	`NCT03325296` - Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.	Phase 2
Recruiting	`NCT05635266` - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Enrolling by invitation	`NCT05745389` - CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry
Recruiting	`NCT04246372` - Tofacitinib for Immune Skin Conditions in Down Syndrome	Phase 2
Not yet recruiting	`NCT06087796` - Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata.	Phase 1
Withdrawn	`NCT03532958` - Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata	Phase 2
Recruiting	`NCT02604888` - Efficacy Study of a Cosmetic Lotion in the Treatment of Alopecia Areata in Males and Females	N/A
Terminated	`NCT01385839` - Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata	N/A
Completed	`NCT00408798` - Treatment of Alopecia Areata of the Scalp With Intradermal Injections of Botulinum Toxin	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms